Company: HURA
Filing Date: 2025-05-23
Form Type: 424B3
Source: 0001193125-25-125499
Chunk: 675

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-23
Form: 424B3
Chunk 675
---
 fees that have yet to be recognized but are expected to be directly attributable to the Mergers were adjusted
for within accumulated deficit in the December 31, 2024 pro forma condensed combined balance sheet to give pro forma effect from recording transaction costs to

450

NOTES TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION

general and administrative expenses during the twelve months ended December 31, 2024 in the pro forma condensed combined statement of operations (refer to adjustmentEE(ii)).

Of the$4,353,000 total of TuHURA’s transaction costs, an aggregate amount of $2,830,552 is expected to be paid in cash at the
close of the Mergers and, as such, $1,522,448 of TuHURA’s estimated transaction costs are expected to remain unpaid. Accordingly, pro forma adjustments of 2,575,000 ($2,830,552 less $255,552 already paid) to the reflect the additional cash paid
at Closing and $1,051,085 to reflect the increase in accounts payable and accrued expenses have been included in the pro forma condensed combined balance sheet as of December 31, 2024.

GRepresents the additional equity issued by Kineta in March 2025 after entering into a securities exchange agreement (the
“Exchange Agreement”) with an existing investor (the “Holder”) pursuant to which Kineta agreed to issue an aggregate of (i) an aggregate of 1,225,323 shares of Kineta Common Stock, and (ii) a pre-funded warrant to purchase up to an aggregate of 655,019 shares of Kineta Common Stock, in exchange for certain outstanding warrants (the “Prior Warrants”) held by the Holder to purchase up to
2,315,387 Kineta shares (the “Exchange”). While the Exchange only has impacts to the stockholders’ equity of Kineta before the Closing Date of the Mergers, the adjustment is reflected in the pro forma condensed combined financial
information as the terms of the Exchange Agreement also include provisions to ensure that the Holder will vote in favor of the approval of the transactions contemplated in the Merger Agreement.

The Prior Warrants as well as both the newly issued Kineta common shares and pre-funded warrants were
determined to be equity-classified. Accordingly, the accounting for the exchange is recognized as a capital transaction with net zero impact to Kineta’s total equity. The 1,225,323 shares issued by